Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : FDA okays Regeneron COVID-19 antibody as preventive in high-risk settings

07/30/2021 | 03:00pm EDT

July 30 (Reuters) - The U.S. Food and Drug Administration has expanded the emergency use authorization of Regeneron Pharmaceuticals Inc's COVID-19 antibody cocktail, enabling its use as a preventive treatment for the illness in certain people.

The company said the authorization enables the therapy to be used in people exposed to an infected individual, or who are at high risk of exposure to an infected individual in settings such as nursing homes or prisons.

The combo therapy, REGEN-COV, was authorized in November for emergency use to treat people with mild-to-moderate COVID-19 in the United States.

REGEN-COV, a combination of casirivimab and imdevimab, protected household contacts from exposure to SARS-CoV-2, with 72% protection against symptomatic infections in the first week, and 93% after that, according to trial data released by the company in April.

Regeneron said the expanded authorization will help address the needs of immunocompromised people, including those taking immunosuppressive medicines, whose bodies may not mount an adequate response to COVID-19 vaccination.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Devika Syamnath)


ę Reuters 2021
All news about REGENERON PHARMACEUTICALS
09/21EU signs joint procurement deal for Eli Lilly COVID-19 treatment
RE
09/21REGENERON PHARMACEUTICALS : BMO Capital Adjusts Regeneron Pharmaceuticals' Price Target to..
MT
09/21REGENERON PHARMACEUTICALS : New Dupixent« (dupilumab) Data in Patients as Young as Six Yea..
PR
09/20REGENERON PHARMACEUTICALS : Esmo late-breaking data show libtayo (cemiplimab) and chemothe..
AQ
09/20SANOFI : - ESMO late-breaking data show Libtayo (cemiplimab) and chemotherapy first-line t..
AQ
09/20Biogen, Samsung Bioepis Get FDA OK for Lucentis Biosimilar
DJ
09/20SANOFI : Regeneron, Sanofi Say Lung Cancer Drug Libtayo Improves Overall Patient Survival ..
MT
09/20SANOFI : Regeneron's Libtayo Combo Extends Lung Cancer Patients' Lives In Phase 3 Study
MT
09/17INSIDER SELL : Regeneron Pharmaceuticals
MT
09/16REGENERON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 13 864 M - -
Net income 2021 6 822 M - -
Net cash 2021 6 794 M - -
P/E ratio 2021 10,3x
Yield 2021 -
Capitalization 67 262 M 67 262 M -
EV / Sales 2021 4,36x
EV / Sales 2022 4,75x
Nbr of Employees 9 635
Free-Float 82,0%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | MarketScreener
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 646,95 $
Average target price 681,41 $
Spread / Average Target 5,33%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS33.91%67 262
GILEAD SCIENCES, INC.23.12%88 970
BIONTECH SE318.73%81 878
WUXI APPTEC CO., LTD.35.75%69 413
VERTEX PHARMACEUTICALS-21.38%48 168
BEIGENE, LTD.50.36%37 076